Magazine Article | February 1, 2021

RNA's Rousing New Adventure

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Dicerna is a case in point: RNA-based and related medicines — mRNA, RNAi, CRISPR, gene and cell therapies — are now receiving new attention and support after years of struggle and setbacks.

The change is largely due to many companies doing extensive work to solve the associated problems and improve the technologies behind such products. But, more recently, the COVID-19 pandemic and mRNA vaccines developed to fight it have generated a fresh wave of acceptance for RNA- and gene-based therapies.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader